CN Patent

CN113368044A — 物理和化学稳定的吉维诺司他口服混悬液

Assigned to Itafa Mark Ag · Expires 2021-09-10 · 5y expired

What this patent protects

本发明涉及物理和化学稳定的吉维诺司他口服混悬液，特别公开吉维诺司他(二乙基‑[6‑(4‑羟基氨甲酰基‑苯基氨甲酰氧基甲基)‑萘‑2‑基‑甲基]‑氯化铵)的物理和化学稳定的口服液体制剂，以及其制备方法。该口服制剂为水性混悬液形式，并且含有吉维诺司他和/或其药学上可接受的盐和/或衍生物、至少一种润湿剂和/或至少一种密度赋予剂。该制剂适合于用于全身性治疗作用的口服施用。

USPTO Abstract

本发明涉及物理和化学稳定的吉维诺司他口服混悬液，特别公开吉维诺司他(二乙基‑[6‑(4‑羟基氨甲酰基‑苯基氨甲酰氧基甲基)‑萘‑2‑基‑甲基]‑氯化铵)的物理和化学稳定的口服液体制剂，以及其制备方法。该口服制剂为水性混悬液形式，并且含有吉维诺司他和/或其药学上可接受的盐和/或衍生物、至少一种润湿剂和/或至少一种密度赋予剂。该制剂适合于用于全身性治疗作用的口服施用。

Drugs covered by this patent

givinostat-hydrochloride (GIVINOSTAT HYDROCHLORIDE)

Patent Metadata

Patent number: CN113368044A
Jurisdiction: CN
Classification: —
Expires: 2021-09-10
Drug substance claim: No
Drug product claim: No
Assignee: Itafa Mark Ag
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.